Zealand and Roche said petrelintide achieved weight loss of up to 10.7% at week 42 in a Phase 2 clinical trial. - Company Supplied ImageZealand Pharma shares fell sharply after the Danish biotechnology company reported weaker-than-expected data from a midstage study of an obesity drug candidate it is jointly developing with Roche Holding. Shares in Zealand plunged as much as 32% shortly after the opening bell on Friday, and have more than halved their value over the past year. The trial met its primary goal and the drug showed a tolerability profile comparable to placebo, the companies said. Petrelintide’s efficacy fell short of both the 13% to 15% weight loss analysts at Jefferies expected and the more than 15% investors likely hoped for, the investment bank said in a research note.

Source: Wall Street Journal March 06, 2026 14:30 UTC